Ophthalmic Business News

Celanese has entered into an agreement with Glaukos to supply the VitalDose drug delivery platform for Glaukos’ iDose TR, according to a press release.

Brim Biotechnology submitted an investigational new drug application to the FDA for BRM424 for the treatment of neurotrophic keratitis, according to a press release.

In this episode, I chat with Nancy Lurker, CEO and board director, about EyePoint Pharmaceuticals and their latest treatments and trials.

The FDA granted orphan drug designation for HG004, a gene replacement therapy for the treatment of inherited retinal diseases caused by RPE65 mutations, HuidaGene Therapeutics announced in a press release.

MCO-010 demonstrated positive topline results for vision restoration in patients with advanced retinitis pigmentosa, according to a press release from Nanoscope Therapeutics.

At the end of 2022, Congress passed a massive 4,155-page spending package that included SECURE Act 2.0, which provided numerous improvements to retirement savings and distribution rules.

The FDA granted breakthrough device designation to the Prima System, an implant designed to partially restore vision in patients with atrophic dry age-related macular degeneration, Pixium Vision announced.

The FDA approved a twice-daily dosing option for Vuity for the treatment of presbyopia, AbbVie announced.

Warren Foust has been named as chief operating officer of STAAR Surgical.

Visus Therapeutics completed enrollment in a pivotal phase 3 trial investigating Brimochol PF for the treatment of presbyopia.